Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin Solomon(Peter MacCallum Cancer Centre), Benjamin Besse(Université Paris-Sud), Todd M. Bauer(Tennessee Oncology), Enriqueta Felip(Vall d'Hebron Institute of Oncology), Ross A. Soo(National University Hospital), D. Ross Camidge(The Medical Center of Aurora), Rita Chiari(Azienda Ospedaliera di Perugia), Alessandra Bearz, Chia‐Chi Lin(National Taiwan University Hospital), Shirish M. Gadgeel(University of Michigan–Ann Arbor), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Eng Huat Tan(National Cancer Centre Singapore), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Leonard P. James(Pfizer (United States)), Jill S. Clancy(Pfizer (United States)), Antonello Abbattista(Pfizer (Italy)), Jean-François Martini(Pfizer (United States)), Joseph Chen(Pfizer (United States)), Gerson Peltz(Pfizer (United States)), Holger Thurm(Pfizer (United States)), Sai‐Hong Ignatius Ou(University of California, Irvine), Alice T. Shaw(Massachusetts General Hospital)
Cited by 787
Abstract
Related Papers
No related papers found
Powered by citation graph analysis